Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity

Anthracycline drugs such as doxorubicin (DOX) and daunorubicin remain some of the most active wide-spectrum and cost-effective drugs in cancer therapy. However, colorectal cancer (CRC) cells are inherently resistant to anthracyclines which at higher doses cause cardiotoxicity. Our recent studies ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonowal, Himangshu, Pal, Pabitra B., Wen, Jian-Jun, Awasthi, Sanjay, Ramana, Kota V., Srivastava, Satish K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466629/
https://www.ncbi.nlm.nih.gov/pubmed/28600556
http://dx.doi.org/10.1038/s41598-017-03284-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466629/
https://www.ncbi.nlm.nih.gov/pubmed/28600556
http://dx.doi.org/10.1038/s41598-017-03284-w

Ejemplares similares